alendronate has been researched along with ym 529 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| Fukunaga, M | 1 |
| Matsumoto, T | 1 |
| Hagino, H; Itabashi, A; Matsumoto, T; Minamide, T; Mizunuma, H; Morii, H; Nakamura, T; Nishizawa, Y; Ohashi, Y; Shiraki, M; Sone, T; Taketani, Y | 1 |
| Amagase, K; Inaba, A; Ishikawa, Y; Murakami, T; Nukui, K; Senta, T; Takeuchi, K | 1 |
| Okamoto, K; Okimoto, N; Sakai, A; Yoshioka, T | 1 |
| Imano, M; Itoh, T; Komai, M; Mukai, J; Nishida, S; Ogawa, N; Satou, T; Tsubaki, M | 1 |
| Iwata, K; Mashiba, T; Nozaki, K; Tanaka, M; Yamagami, Y; Yamamoto, T | 1 |
| Fujiwara, D; Imano, M; Itoh, T; Komai, M; Mashimo, K; Mukai, J; Nishida, S; Ogawa, N; Sakaguchi, K; Sakamoto, K; Satou, T; Shimaoka, H; Takeda, T; Tsubaki, M | 1 |
| Igase, M; Kohara, K; Miki, T; Ochi, M; Ohara, M; Okada, Y; Tabara, Y; Takita, R | 1 |
| Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T | 1 |
| Ishimoto, T; Matsugaki, A; Nakano, T; Tanaka, M | 1 |
| Ebina, K; Hashimoto, J; Hirao, M; Kaneshiro, S; Noguchi, T; Yoshikawa, H; Yukioka, M | 1 |
| Hyodo, K; Kamada, H; Mishima, H; Nishino, T; Nozawa, D; Yamazaki, M | 1 |
| Iwata, K; Mashiba, T; Saito, M; Tanaka, M; Yamagami, Y; Yamamoto, T | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
2 review(s) available for alendronate and ym 529
| Article | Year |
|---|---|
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Topics: Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Peptides | 2009 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
4 trial(s) available for alendronate and ym 529
| Article | Year |
|---|---|
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2009 |
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Topics: Aged; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Gastrointestinal Tract; Humans; Imidazoles; Osteoporosis, Postmenopausal; Pain Measurement; Peptides; Surveys and Questionnaires | 2013 |
Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Ankle Brachial Index; Atherosclerosis; Bone Density Conservation Agents; Brachial Artery; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Prospective Studies; Pulsatile Flow; Treatment Outcome | 2014 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Patient Preference; Risedronic Acid | 2016 |
13 other study(ies) available for alendronate and ym 529
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Topics: Alendronate; Animals; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Imidazoles; Male; Nitrogen; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2011 |
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density Conservation Agents; Cell Line, Tumor; Cell Nucleus; Cell Survival; Diphosphonates; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematologic Neoplasms; Humans; Imidazoles; MAP Kinase Signaling System; Membrane Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Prenylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Diphosphonates; Female; Femur; Imidazoles; Lumbar Vertebrae; Macaca fascicularis; Ovariectomy | 2013 |
Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.
Topics: Alendronate; Animals; Apoptosis; Bone Diseases, Metabolic; Diphosphonates; Humans; Imidazoles; Macrophage Colony-Stimulating Factor; Macrophages; MAP Kinase Signaling System; Mice; Nitrogen; Oncogene Protein v-akt; Osteoclasts; Polyisoprenyl Phosphates; RANK Ligand | 2014 |
Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate.
Topics: Alendronate; Animals; Apatites; Area Under Curve; Biomarkers; Bone Density; Bone Remodeling; Cortical Bone; Crystallography; Diphosphonates; Female; Imidazoles; Lumbar Vertebrae; Macaca fascicularis; Osteocalcin; Ovariectomy; Tibia; X-Ray Diffraction | 2016 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Preference; Prospective Studies; Risedronic Acid | 2016 |
Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femoral Fractures; Femur; Glucocorticoids; Humans; Imidazoles; Japan; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risedronic Acid | 2017 |
Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Remodeling; Collagen; Cross-Linking Reagents; Diphosphonates; Female; Imidazoles; Lumbar Vertebrae; Macaca fascicularis; Organ Size; Ovariectomy; Stress, Mechanical | 2017 |